Mkts

Nurix Therapeutics, Inc.

NASDAQ: NRIX
$14.73-0.75 (-4.84%)
As of Nov 16, 4:00 PM ET

Key statistics

Day range
14.6815.68
52-week range
12.0128.23
Today
Open15.34
Previous close14.73
Volume—
Valuation
Market cap1.69B
P/E ratio5.74×
EPS (TTM)2.31
Income & risk
Dividend / yield—
Beta1.82
Avg volume2.01M
Discussion

NRIX News

Stories mentioning NRIX from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ2 '26May 31Q1 '26Feb 28Q4 '25Nov 30Q3 '25Aug 31Q2 '25May 31Q1 '25Feb 28Q4 '24Nov 30Q3 '24Aug 31
Income Statement
Revenue9,0436,25213,5777,89444,05618,45313,28412,588
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development87,65384,13783,02486,12078,09669,66367,22455,481
Sales General & Admin
Total Operating Expenses103,24798,74796,67299,27992,37881,31777,94167,199
Operating Income (Loss)(94,204)(92,495)(83,095)(91,385)(48,322)(62,864)(64,657)(54,611)
Interest Income
Interest Expense
Other Expense
Pretax Income(89,806)(78,221)(86,421)(42,704)(56,351)(58,541)(48,874)
Tax Provision(271.00)0.000.000.00760.000.008.0082.00
Net Income (Loss)(89,535)(87,174)(78,221)(86,421)(43,464)(56,351)(58,549)(48,956)
Earnings Per Share (Basic)(0.81)(0.79)(0.90)(1.03)(0.52)(0.67)(0.87)(0.67)
Earnings Per Share (Diluted)(0.81)(0.79)(0.90)(1.03)(0.52)(0.67)(0.87)(0.67)
Weighted Average Shares Outstanding (Basic)111,084110,07286,66784,15983,88283,56167,12072,779
Weighted Average Shares Outstanding (Diluted)111,084110,07286,66784,15983,88283,56167,12072,779

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About NRIX

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is a stock listed on the Nasdaq Stock Market under the ticker symbol NRIX. It last traded at $14.73 (Nov 16, 2026, 4:00 PM ET), down 4.8% on the day. That gives Nurix Therapeutics a market capitalisation of $1.7B and a price-to-earnings ratio of 5.7.

Over the past 52 weeks NRIX has traded between $12.01 and $28.23.

Revenue for the quarter ended May 31, 2026 was $9.0M; a net loss of $89.5M. Revenue was down 79.5% from $44.1M in the quarter ended May 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
May 31, 2026$9.0M-$89.5M-990.1%
Feb 28, 2026$6.3M-$87.2M-1394.3%
Nov 30, 2025$13.6M-$78.2M-576.1%
Aug 31, 2025$7.9M-$86.4M-1094.8%

From Nurix Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…